BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1–SLC7A11–NADPH redox axis
DARU Journal of Pharmaceutical Sciences · 2026
DOI: 10.1007/s40199-026-00663-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift DARU Journal of Pharmaceutical Sciences, 2026. Verfasst von Ranran Xue und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China. Hauptthemen laut MEDLINE: Quinolines, Phenylurea Compounds, Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Acquired resistance limits the efficacy of lenvatinib in hepatocellular carcinoma (HCC). This study evaluated whether GLUT1 inhibition by BAY-876 reverses lenvatinib resistance by disrupting SLC7A11-associated redox buffering. METHODS: Lenvatinib-resistant HuH-7-LR and Hep 3B-LR cells were generated by stepwise drug exposure. Drug sensitivity, combination synergy, glucose uptake, colony formation, migration, ATP, NADPH/NADP⁺ and GSH/GSSG ratios, intracellular thiols, ROS, apoptosis, gene and protein expression, N-acetyl-L-cysteine (NAC) rescue, and SLC7A11 knockdown were evaluated. RESULTS: Resistant cells exhibited increased lenvatinib IC₅₀ values, glucose uptake, and GLUT1/SLC7A11 expression. BAY-876 preferentially inhibited glucose uptake and viability in resistant cells and restored lenvatinib sensitivity to near-parental levels. Combined treatment produced synergistic growth inhibition, reduced colony formation and migration, depleted ATP and NADPH, disrupted GSH/GSSG balance, decreased intracellular thiols, and increased ROS. It also induced apoptosis, evidenced by Annexin V positivity, caspase-3/7 activation, BAX induction, BCL2 suppression, and PARP/caspase-3 cleavage. NAC partially restored viability and redox balance. SLC7A11 knockdown reduced BAY-876-associated thiol depletion and ROS accumulation, supporting an SLC7A11-dependent redox component. CONCLUSION: BAY-876 resensitized lenvatinib-resistant HCC cells by restricting glucose uptake, disrupting NADPH-dependent redox buffering, and promoting redox stress-induced apoptosis. These findings support the GLUT1-SLC7A11-NADPH axis as an in vitro therapeutic vulnerability, while definitive evidence of disulfidptosis requires further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Hospital of Nanjing, Affiliated to Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Pharmacy, The Second People's Hospital of Changzhou, the Third Affiliated Hospital of Nanjing Medical University, Changzhou, China. lin377499@163.com.
Zitieren
APA
Xue, R., & Lin, Y. (2026). BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1–SLC7A11–NADPH redox axis. DARU Journal of Pharmaceutical Sciences. https://doi.org/10.1007/s40199-026-00663-5
Vancouver
Xue R, Lin Y. BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1–SLC7A11–NADPH redox axis. DARU Journal of Pharmaceutical Sciences. 2026. doi:10.1007/s40199-026-00663-5
BibTeX
@article{Xue2026,
author = {Xue, Ranran and Lin, Ying},
title = {BAY-876 restores lenvatinib sensitivity in resistant hepatocellular carcinoma cells by disrupting the GLUT1–SLC7A11–NADPH redox axis},
journal = {DARU Journal of Pharmaceutical Sciences},
year = {2026},
doi = {10.1007/s40199-026-00663-5}
}
EUVIMED